These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1745 related articles for article (PubMed ID: 29061175)

  • 61. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma.
    Lopez RR; Pan SH; Hoffman AL; Ramirez C; Rojter SE; Ramos H; McMonigle M; Lois J
    Arch Surg; 2002 Jun; 137(6):653-7; discussion 657-8. PubMed ID: 12049535
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
    Lai Z; Huang Y; Wen D; Lin X; Kan A; Li Q; Wei W; Chen M; Xu L; He M; Shi M
    BMC Med; 2022 Oct; 20(1):415. PubMed ID: 36310160
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
    J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
    J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.
    Wu Y; Zheng S; Zhang Z; Chen G; Chen X; Zheng T; Guo X; Chen H; Wang M; Xie X; Zhang B
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295504
    [No Abstract]   [Full Text] [Related]  

  • 70. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.
    Zhu S; Yu Y; Yang M; Liu X; Lai M; Zhong J; Zhao X; Lu L; Liu Y
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):423-434. PubMed ID: 38651280
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; 110(12):7860-70. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
    World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
    Chen CS; Li FK; Guo CY; Xiao JC; Hu HT; Cheng HT; Zheng L; Zong DW; Ma JL; Jiang L; Li HL
    Oncotarget; 2016 Feb; 7(6):7241-52. PubMed ID: 26769845
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
    Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.